LC-MS - Articles and news items

Thermo Fisher Scientific

Thermo Fisher Scientific Receives IVDD CE Mark for its Thermo Scientific Prelude MD HPLC, Endura MD Mass Spectrometer and ClinQuan MD Software

Supplier news / 10 September 2015 / Thermo Fisher Scientific

Now available to clinical laboratories in Europe for general in vitro diagnostic use …

Increasing Throughput and Sensitivity of LC-MS assays with a focus on MS optimisation and novel LC strategies

Webinars / 13 July 2015 / Sciex

Simplifying peptide quantification with automated optimisation of MRM transitions and advantages of Micro flow LC to maximise LC-MS performance…

LC-MS Supplement

LC-MS: In-depth focus 2015

Chromatography, Issue 2 2015, Supplements / 20 April 2015 / David Elder, Phil Borman, George Okafo, William McDowell, Hanne Røberg-Larsen

In this free-to-view LC-MS in-depth focus, we delve into the world of glycans, and how their natural complexity necessitates sophisticated sequencing techniques, while another article aims to demonstrate the versatility of LC-MS and the ease with which it can be combined with a variety of MS systems, focusing particularly on nanoLC…


Pharmaceutical proteomics: a journey from discovery and characterisation of targets to development of high-throughput assays

Issue 6 2013, Proteomics / 15 December 2013 / Joerg Reinders, Institute of Functional Genomics, University of Regensburg

Proteomics has evolved during the last few years from a time-intensive, cost-intensive and hard-to-reproduce technique in basic research to a versatile and reliable tool in various areas of pharmaceutical research. The exploding progress in mass-spectrometry-compatible protein and peptide-separation methods led to the development of new approaches particularly suited for monitoring a multitude of specific targets in highly complex matrices in a highly sensitive, specific and parallel fashion. These new technologies have caused a paradigm shift in proteomics from mostly gel-based, hypothesis-generating studies towards fast, cost-effective and mostly LC-MS-based assays. Therefore, proteomics emerges for pharmaceutical researchers aiming to identify and verify proteinaceous biomarkers as proteomics technology comes of age…

EPR Screening Supplement 2013

Implementation of high-throughput quality control processs within compound management

Chromatography, Issue 4 2011 / 31 August 2011 / Jerome Giovannoni and J.M. Peltier, Novartis

The constant growth of compound collections, combined with screening efforts on more challenging targets, is creating an increasing demand for quality control in order to ensure the integrity of the compound solutions being tested. This is true throughout the early drug discovery pipeline, from hit identification to lead nomination. Novartis has recently updated its QC capabilities by creating two High Throughput Quality Control (QC) laboratories, enabling a systematic QC at three critical stages: 1. Production of DSMO stock solutions used in High Throughput Screening (HTS); 2. Creation of dilution series for Hit-Validation; 3. Production of DMSO solutions prepared in the Novartis ‘Compound Hubs’ for the Hitto- Lead optimisation stage of projects. High-throughput LC-MS methods were developed to confirm the identity and the purity of ca. 500,000 samples/year in a highly automated fashion…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...